A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer
| Autor: | Cecilie, Holländer, Lene, Baeksgaard, Morten, Sorensen, Per, Albertsson, Lars, Damstrup, Ulrik, Lassen |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Dose-Response Relationship Drug Esophageal Neoplasms Organoplatinum Compounds Antibodies Monoclonal Cetuximab Chemoradiotherapy Middle Aged Antibodies Monoclonal Humanized Drug Administration Schedule Oxaliplatin Antineoplastic Combined Chemotherapy Protocols Humans Female Uracil Aged Tegafur |
| Zdroj: | Anticancer research. 32(9) |
| ISSN: | 1791-7530 |
| Popis: | To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of concurrent chemoradiotherapy and cetuximab in patients with non-resectable locally advanced esophageal cancer.Escalating doses of oxaliplatin every second week and daily tegafur/uracil were given concurrently with radiotherapy, 59.4 Gy in 33 fractions. Cetuximab was given on day 15 (400 mg/m(2)) and weekly (250 mg/m(2)) during radiotherapy. Fixed doses of oxaliplatin (130 mg/m(2)) and tegafur/uracil (300 mg/m(2)) were administered before, and after radiotherapy.Eleven patients were included in the study; two were excluded due to allergic reactions to cetuximab. In DL2 (tegafur/uracil 300 mg/m(2), oxaliplatin 30 mg/m(2)) two grade 3/4 fistula and one grade 3 neuropathy were observed. Six patients were enrolled in DL1 (tegafur/uracil 150 mg/m(2)/, oxaliplatin 30 mg/m(2)) with no DLTs. Four out of 9 patients had complete response.Concomitant chemoradiotherapy and cetuximab had significant activity. DL1 was established as the MTD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|